2 New Pathology MIPS Measures
for MSN's CMS Approved QCDR
MSN Healthcare Solutions works closely with our pathology partners to develop new MIPS Measures for MSN’s – CMS approved – QCDR.
We were successful in adding the following two measures for 2022:
- QMM21:
Incorporating results of concurrent studies into Final Reports for Bone Marrow Aspirate of patients with Leukemia, Myelodysplastic syndrome, or Chronic Anemia - QMM22:
Multi-gene Next-generation Sequencing Panel Recommended on Fine Needle Aspirations (FNA) of Thyroid Nodule(s) with indeterminate Cytology
MSN Healthcare Solutions is a national provider of pathology billing and revenue cycle services. If your current service contract is up for renewal, why not spend a few minutes with us to discuss how our services may benefit your practice.
CONTACT US ABOUT OUR PATHOLOGY SERVICES
